Transforming growth factor beta-1 (TGF-beta1)

Transforming growth factor beta-1 (TGF-beta1) is a potent pleiotropic cytokine belonging to the TGF-beta superfamily, playing a central role in regulating cell growth, differentiation, and immune function (UniProt P01137). It is synthesized as a precursor protein that is cleaved and stored in the extracellular matrix as part of a latent complex, requiring activation by integrins or proteases to exert its biological effects (Massagué, 2012). In healthy tissues, TGF-beta1 acts as a tumor suppressor by inhibiting epithelial cell proliferation; however, in advanced cancers, it promotes tumor progression by inducing epithelial-mesenchymal transition (EMT) and suppressing anti-tumor immunity (Akhurst & Hata, 2012). Beyond oncology, TGF-beta1 is a primary driver of pathological fibrosis in organs such as the lungs, liver, and kidneys by stimulating the production of extracellular matrix components (Meng et al., 2016). Therapeutic strategies targeting TGF-beta1 include neutralizing monoclonal antibodies and ligand traps, which aim to mitigate its pro-fibrotic and immunosuppressive effects. However, drug development is challenged by the cytokine's complex homeostatic roles, leading to potential safety concerns like skin lesions and cardiovascular toxicity (Connolly et al., 2012).

Other names

TGFB1CEDDPD1TGF-beta-1Transforming growth factor beta 1LAP

Inhibition of TGF-beta1 signaling through direct ligand neutralization or sequestration, preventing its binding to TGF-beta receptors (Type I and II) and subsequent activation of SMAD-dependent and SMAD-independent pathways (Akhurst & Hata, 2012).